Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Recommendation of “Reduce” from Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned a consensus recommendation of “Reduce” from the fifteen ratings firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $491.2727.

Several analysts have weighed in on MEDP shares. TD Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Robert W. Baird set a $613.00 target price on Medpace in a research report on Friday, October 24th. Mizuho set a $660.00 price target on shares of Medpace in a report on Friday, January 9th. BMO Capital Markets assumed coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st.

Insider Buying and Selling at Medpace

In related news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 351,235 shares of company stock valued at $211,280,506. 20.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently made changes to their positions in MEDP. Fifth Third Wealth Advisors LLC lifted its stake in shares of Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the period. BOKF NA increased its holdings in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares in the last quarter. HighPoint Advisor Group LLC raised its position in shares of Medpace by 2.8% in the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after acquiring an additional 22 shares during the period. Kaufman Rossin Wealth LLC boosted its stake in shares of Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after acquiring an additional 26 shares in the last quarter. Finally, Portside Wealth Group LLC boosted its stake in shares of Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after acquiring an additional 27 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $602.06 on Thursday. The company’s fifty day moving average price is $583.97 and its 200-day moving average price is $524.60. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92. The firm has a market capitalization of $16.96 billion, a PE ratio of 42.10, a price-to-earnings-growth ratio of 1.97 and a beta of 1.43.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.